Published in Cancer Treat Rev on September 15, 2010
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST. CPT Pharmacometrics Syst Pharmacol (2013) 0.93
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer (2014) 0.92
Computational oncology - mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol (2015) 0.90
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer (2014) 0.86
A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta Oncol (2015) 0.80
Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol Lett (2016) 0.78
Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach. CPT Pharmacometrics Syst Pharmacol (2014) 0.77
Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients. Int J Mol Sci (2017) 0.75
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. Clin Pharmacokinet (2015) 0.75
Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients? Can Urol Assoc J (2017) 0.75
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? Drugs R D (2017) 0.75
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol (2017) 0.75
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst (2010) 2.12
Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08
Photodynamic therapy in oncology. Oncologist (2006) 2.04
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res (2006) 1.65
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol (2002) 1.64
Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol (2009) 1.61
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 1.60
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol (2006) 1.60
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci (2005) 1.59
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology (2013) 1.57
Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2011) 1.55
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res (2004) 1.51
Drug interactions in oncology. Lancet Oncol (2004) 1.49
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol (2003) 1.49
Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist (2006) 1.43
Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol (2005) 1.41
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther (2007) 1.39
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci (2006) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
Clinical experience with aurora kinase inhibitors: a review. Oncologist (2009) 1.31
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.27
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet (2006) 1.26
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol (2010) 1.25
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res (2007) 1.24
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist (2005) 1.24
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist (2007) 1.23
Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat (2008) 1.21
Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol (2006) 1.21
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res (2002) 1.21
Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat (2011) 1.20
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol (2003) 1.19
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2003) 1.17
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist (2008) 1.17
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res (2006) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther (2002) 1.14
Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist (2006) 1.14
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol (2003) 1.13
Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom (2009) 1.12
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther (2008) 1.11
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs (2008) 1.10
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther (2002) 1.10
Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab Rev (2007) 1.10
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs (2010) 1.09
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther (2002) 1.08
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res (2007) 1.08
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab (2011) 1.08
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol (2004) 1.08
Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem (2003) 1.07
Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res (2010) 1.06
Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol (2002) 1.05
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol (2012) 1.05
Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet (2006) 1.04
Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res (2002) 1.04
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist (2006) 1.03
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res (2012) 1.03
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev (2007) 1.03
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol (2008) 1.02
Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev (2013) 1.01
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol (2009) 1.01
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res (2005) 1.01
Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res (2005) 1.01
Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.00
Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol (2011) 1.00
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet (2014) 1.00
Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol (2012) 0.99
Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev (2008) 0.98
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anticancer Drugs (2014) 0.98
Application of PET/CT in the development of novel anticancer drugs. Oncologist (2008) 0.98
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer (2011) 0.98
MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer (2014) 0.98
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol (2010) 0.97